search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Detection of Barrett¡¯s esophagus through exhaled breath using an electronic nose device (AeoNoseTM)


- candidate number28385
- NTR NumberNTR6928
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR28-dec-2017
- Secondary IDs2017-3505 CMO Radboudumc
- Public TitleDetection of Barrett¡¯s esophagus through exhaled breath using an electronic nose device (AeoNoseTM)
- Scientific TitleDetection of Barrett¡¯s Esophagus through Exhaled Breath using an Electronic Nose Device (AeoNoseTM)
- ACRONYMeNose
- hypothesis
- Healt Condition(s) or Problem(s) studiedBarrett's esophagus, Gastroesophageal reflux Disease (GERD), Esophageal Adenocarcinoma (EAC)
- Inclusion criteriaSubjects, who are:
- Aged 18 years or older.
- Able to give signed informed consent.

1. Patients with known Barrett's Esophagus (BE), who are.
- Diagnosed with a BE segment >1cm in maximal extent endoscopically (CxM1).
- Histology showing evidence of intestinal metaplasia without presence of dysplasia.
- Undergoing clinically indicated (surveillance) endoscopy.

2. Individuals with reflux symptoms without BE, who are.
- Undergoing clinically indicated diagnostic endoscopy due to upper gastrointestinal symptoms (non-acute symptoms of heartburn, pain in the epigastric region or bloating, with the cause likely to be located in the upper gastrointestinal tract).
- GerdQ self-assessment questionnaire score ¡Ý 8.

3. Healthy individuals without BE and without reflux symptoms, who are
- Undergoing clinically indicated diagnostic endoscopy.
- GerdQ self-assessment questionnaire score < 6.
- Exclusion criteria•Patients with a history of any type of malignancy (not including basal-cell skin cancer (BCC) and squamous-cell skin cancer (SCC))
• Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation) or endoscopic mucosal resection.
• Patients with history of esophageal or gastric resection or surgery which has changed the esophageal anatomy.
•Patients who are unable to perform breathing maneuver needed for Aeonose-analysis of exhaled air
- mec approval receivedno
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlNot applicable
- group[default]
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-jan-2018
- planned closingdate1-jul-2018
- Target number of participants225
- InterventionsDevice: Aeonose
An electronic nose device is an artificial olfactory system that analyses volatile organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
- Primary outcomeThe ability to distinguish between patients with BE, healthy individuals, and patients with reflux symptoms by eNose in terms of sensitivity, specificity and accuracy.
- Secondary outcomeCross-validated accuracy with which the eNose can distinguish between patients with BE, healthy individuals and patients with reflux symptoms, defined as the percentage of correctly classified patients using the leave-some out method.
- Acceptance rate of using the eNose
- Timepointstime frame: 1 year
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD Yonne Peters
- CONTACT for SCIENTIFIC QUERIESMD Peter D. Siersema
- Sponsor/Initiator Radboud University Medical Center Nijmegen
- Funding
(Source(s) of Monetary or Material Support)
Radboud University Medical Center Nijmegen
- Publications
- Brief summaryThe current study will be a multi-center cross-sectional, exploratory proof of principle study to explore whether an electronic nose device (Aeonose (the eNose Company, Zutphen, the Netherlands)) is able to distinguish patients with BE from those without BE by VOC analysis of patient breath samples.
- Main changes (audit trail)
- RECORD28-dec-2017 - 9-mrt-2018


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl